Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03393845
Title Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nancy Chan, MD
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.